Fundz

TRIMTECH Therapeutics raised $31M in a seed funding round led by Cambridge Innovation Capital and SV Health Investors’ Dementia Discovery Fund to advance targeted protein degradation for neurodegenerative diseases.

PRIVATEMar 05, 2025

Amount Raised

$31 Million

Round Type

Seed

CambridgeBiotechnologyHealth CareTherapeutics

Investors

MP Healthcare Venture ManagementEli Lilly And CompanyPfizer VenturesM VenturesCambridge Enterprise VenturesStart CodonSV Health Investors' Dementia Discovery FundCambridge Innovation Capital

Description

TRIMTECH Therapeutics announced the closing of its $31 million seed funding round to support the development of its pipeline for treating neurodegenerative diseases. This investment was led by notable investors including Cambridge Innovation Capital and SV Health Investors.

Who to call at TRIMTECH Therapeutics, and when

A new round usually means TRIMTECH Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day TRIMTECH Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at TRIMTECH Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at TRIMTECH Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

TRIMTECH Therapeutics

Location

Cambridge, England, United Kingdom

About

TRIMTECH Therapeutics is a biotech company focused on harnessing targeted protein degradation for the treatment of neurodegenerative diseases. The company has developed a pipeline of CNS-penetrant therapeutics based on their unique degrader molecules known as TRIMTACs. By leveraging the properties of the E3 ubiquitin ligase TRIM21, TRIMTECH aims to address significant treatment gaps for conditions like Alzheimer's and Huntington's disease. Founded by prominent organizations and experts, TRIMTECH is committed to advancing innovative therapies for complex diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment TRIMTECH Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsAlexander L., SVP Head of ChemistrySee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for TRIMTECH Therapeutics's next move

See what Strategic adds

TRIMTECH Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.